Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Saskatchewan

Saskatoon, Saskatchewan, S7N oW8, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of asthma; stable and controlled
FEV1 greater than or equal to 65% predicted

Exclusion criteria

Concomitant lung disease other than asthma

Treatment and study plan

ipratropium bromide

Drug

2 puffs (40 micrograms) 2 puffs (0micrograms)

Other names: Atrovent HFA Inhalation Aerosol

Placebo

Drug

Matched placebo

Primary outcomes

methacholine PC20

Time frame: 6hours and 12 hours post inhalation

Sponsors and collaborators

Lead sponsor

University of Saskatchewan

Other

Collaborators

Royal University Hospital Foundation

Registry information

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Jan 31, 2008
Registry last updated: Jan 7, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed